Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesReproductive Health & FertilityDivision of Financial Regulation RHEA Coverage Upd…
    Ask Trek AI about this page
    CurrentDivision of Financial Regulation, Department of Consumer and Business ServicesPolicy DFR 2025-3

    Director's expectations for health benefit plans under the Oregon Reproductive Health Equity Act

    Customize your policy alerts

    Sign up for Division of Financial Regulation, Department of Consumer and Business Services Policy DFR 2025-3 alerts

    Get alerted when Policy DFR 2025-3 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Director's expectations for health benefit plans in Oregon to provide reproductive health services, drugs, devices, products, and procedures described in ORS 743A.067 without cost sharing, and guidance on permissible management and exceptions. Applies to all entities offering health benefit plans in Oregon.

    Policy Summary
    PayerDivision of Financial Regulation, Department of Consumer and Business Services
    PolicyDirector's expectations for health benefit plans under the Oregon Reproductive Health Equity Act
    Policy CodePolicy DFR 2025-3
    Change TypeNo material change
    Effective DateMar 24, 2025
    Last ReviewMar 24, 2025
    Next Review Date
    Key ActionDo not require prior authorization, step therapy, or other utilization review for medically appropriate covered contraceptives; provide prescribed alternatives when a covered therapeutic equivalent is medically inadvisable.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ORS 743A.067statutory source
    No prior authorizationno prior auth
    50%refill threshold
    12-monthsupply example

    Coverage Criteria for Reproductive Health Services

    Preventive and screening services

    Covered when services fall within ORS 743A.067(2) and applicable USPSTF/HRSA recommendations, without limitation by sex or gender.

    RHEA preventive coverage: Coverage required for screenings and preventive services described in ORS 743A.067(2); for screenings of anemia, urinary tract infection, and pregnancy plans must cover any test for the condition (including diagnostic tests and tests outside preventive settings); for other screenings coverage must include services required by 42 U.S.C. 300gg-13 (USPSTF A/B and HRSA) and may not be limited by the enrollee's sex or gender.

    Plans compliant if they cover USPSTF/HRSA required services without sex/gender limits.

    Contraceptive coverage

    Covered without cost sharing: all FDA-approved contraceptive drugs, devices, and products, including when prescribed for non-contraceptive medical reasons.

    Base requirement: Plans must cover any FDA-approved contraceptive drug, device, or product without prior authorization, step therapy, or other utilization review techniques for medically appropriate covered contraceptives; coverage includes counseling, education, administration, monitoring, management of side effects, insertion and removal, and related services.

    Includes contraceptives prescribed for reasons other than preventing pregnancy and those necessary to preserve life or health.

    Therapeutic equivalents option: If a contraceptive has one or more therapeutic equivalents, a plan may cover either the requested contraceptive or one or more therapeutic equivalents, provided at least one therapeutically equivalent version is covered.

    Plans that limit therapeutic equivalents must still provide alternatives when medically inadvisable for a particular enrollee.

    Exceptions and process: When a covered therapeutic equivalent is medically inadvisable for a particular enrollee as determined by the enrollee's provider, the plan must cover the prescribed alternative; carriers that exclude therapeutic equivalents must establish an easily accessible, transparent, and sufficiently expedient provider notification/exceptions process.

    Carrier processes should account for medical exigencies and not be unduly burdensome; director expects carriers to defer to provider determinations except as allowed under ORS 743A.067(7).

    Reasonable medical management (non-contraception/non-abortion)

    Permitted limits and scope of reasonable medical management for services other than contraception and abortion.

    Allowed medical management: Plans may use reasonable medical management techniques to determine frequency, method, treatment, or setting for RHEA services other than contraception and abortion, provided such techniques are consistent with ORS 743A.067(2) and do not result in wholesale or indiscriminate denial of coverage.

    Techniques inconsistent with RHEA include strict numerical limits that ignore medical need and denying services because the enrollee's sex or gender differs from typical USPSTF/HRSA recommendations (e.g., limiting STI screening to once per year when more frequent testing is medically appropriate).

    Contraceptive coverage and utilization management

    Carriers must cover FDA-approved contraceptives and defer to provider-determined medically appropriate alternatives; utilization management constraints and operational expectations are as follows:

    Contraceptive coverage and management: 1) Cover the full range of FDA-approved contraceptives as prescribed; 2) Do not impose prior authorization, step therapy, or other utilization review techniques for medically appropriate covered contraceptives; 3) If a prescribed contraceptive has no therapeutic equivalent, provide coverage without requiring an exemption or prior authorization; 4) If a provider notifies a plan that a covered therapeutic equivalent is medically inadvisable for a patient, the plan must cover the prescribed alternative; 5) Maintain an easily accessible, transparent, and sufficiently expedient exceptions/notification process that is not unduly burdensome on enrollees or providers.

    These expectations implement ORS 743A.067(2)(j)(A)–(D) and the director's interpretations in this bulletin.

    Abortion coverage

    Abortion coverage under RHEA and applicable limitations.

    Abortion coverage: When a carrier is required to cover abortion under RHEA, the carrier must defer to the provider's determination regarding frequency, method, treatment, or setting of an abortion and must not impose cost sharing; the allowance for reasonable medical management does not apply to abortion coverage.

    Carriers should not impose restrictions or delays not explicitly authorized by RHEA.

    HDHP/HSA compatibility

    Guidance on High Deductible Health Plans (HDHPs) and HSA eligibility when accommodating RHEA-covered services.

    HDHP conditions for approval: Under ORS 742.008(3), DCBS may approve HDHP filings that meet federal HSA requirements even if state first-dollar coverage mandates would otherwise conflict, provided the plan complies with the Oregon Insurance Code, applies deductibles as required to maintain HSA eligibility, and aligns with federal preventive service requirements.

    Ensures HDHPs can remain HSA-eligible while accommodating state mandates to the extent not conflicting with federal law.

    CMP cost sharing

    Cost-sharing treatment for Comprehensive Metabolic Panels (CMPs).

    CMP coverage rules: CMPs are not required to be covered without cost sharing unless performed as part of a preventive service; when ordered as part of a preventive service (for example, a well-woman exam), the CMP must be covered without cost sharing in accordance with state and federal preventive care mandates.

    Standard cost sharing may apply when a CMP is not tied to a preventive service.

    RHEA does not require coverage for every health care intervention. Under ORS 743A.067(7), a health benefit plan may exclude coverage for experimental or investigational treatments, clinical trials or demonstration projects (except as provided in ORS 743A.192), treatments that do not conform to acceptable and customary standards of medical practice, treatments for which there is insufficient medical evidence of efficacy, or abortion when the carrier is exempt. When a carrier denies coverage for a RHEA-listed service for one of these reasons, the carrier is expected to document the rationale for the denial and provide the enrollee with the appeal rights required under ORS 743B.250.

    Carriers may not deny coverage or impose cost sharing because a contraceptive was prescribed for a reason other than avoiding pregnancy. ORS 743A.067(5) prohibits treating medications, devices, or products prescribed for non-contraceptive medical indications differently; plans must cover such contraceptives without imposing additional cost sharing or restrictions based on the indication for which the provider prescribed them.

    A carrier may deny coverage only for the limited reasons set out in ORS 743A.067(7). Permissible bases for denial include services that are experimental or investigational, part of a clinical trial or demonstration project (subject to statutory exceptions), not consistent with acceptable medical practice, or lacking sufficient evidence of efficacy. Denials on these grounds should be supported by documentation explaining why the criterion applies to the specific claim.

    Carriers must not apply utilization controls that effectively prevent continuous use of prescribed contraception or that ignore a provider's determination that a covered therapeutic equivalent is medically inadvisable. Examples of prohibited practices include denying a refill in a way that stops continuous use (the division presumes compliance when carriers allow refills at a 50% or lower remaining-usage threshold) and refusing to cover a prescribed therapeutic equivalent after a provider notifies the plan that the covered equivalent is medically inadvisable. Plans are also expected to cover the full amount prescribed (for example, a 12‑month supply) when required by statute.

    Coding and Screening Details

    Preventive screenings (USPSTF/HRSA referenced)mixed
    No codes listed
    Screening coverage — scope and limits
    Scope of screening coveragePlans must cover any test for anemia, urinary tract infection (UTI), and pregnancy, including diagnostic tests and tests not performed in a preventive setting.
    USPSTF/HRSA-based screeningsFor other screenings listed under ORS 743A.067(2)(c), plans must cover preventive screenings without cost share by covering services required under 42 U.S.C. 300gg-13 (USPSTF A/B and HRSA) and may not limit coverage by sex or gender.
    Medical evidence exceptionRHEA does not require coverage for tests for which there is insufficient medical evidence of efficacy or that do not conform to acceptable and customary medical practice (ORS 743A.067(7)).
    Refill-too-soon threshold
    Presumed-compliant refill thresholdCarriers that allow a refill when at least 50% of the previous prescription has been used are presumed to be in compliance with ORS 743A.067(2)(j)(D).

    Provider Actions, Notification & Utilization Management

    Prior Authorization

    No prior authorization for contraception

    Health benefit plans may not require prior authorization, step therapy, or other utilization review techniques for medically appropriate covered contraceptive drugs, devices, or products; plans must provide coverage for FDA‑approved contraceptives without prior authorization when no therapeutic equivalent exists.

    Prior Authorization

    Prohibition on prior authorization for contraceptives

    A carrier may not require prior authorization, step therapy, or other utilization review for medically appropriate covered contraceptive drugs, devices, or products; requiring an exemption request before covering an FDA‑approved contraceptive with no therapeutic equivalent would constitute prohibited prior authorization.

    Step Therapy

    PROHIBITED UTILIZATION REVIEW

    Key Definitions

    Cost sharing
    DefinitionAny expenditure required by or on behalf of an enrollee with respect to a covered benefit, including deductibles, coinsurance, copayments, and similar charges.
    Included examplesIncludes deductibles, coinsurance, and copayments.
    ExclusionsExcludes premiums, balance billing amounts for non-network providers, and spending for non-covered services.
    Therapeutic equivalent
    DefinitionA contraceptive drug, device, or product that the FDA has classified as therapeutically equivalent to another contraceptive in the FDA publication 'Approved Drug Products with Therapeutic Equivalence Evaluations' (the Orange Book).
    SourceFDA Orange Book ('Approved Drug Products with Therapeutic Equivalence Evaluations').

    Background and Scope

    RHEA requires health benefit plans to cover, without cost sharing, the services listed in ORS 743A.067(2). This coverage obligation overlaps with—but in some respects is broader than—federal preventive service mandates (such as USPSTF and HRSA recommendations) because RHEA’s protections apply regardless of an enrollee’s sex or gender and extend to the range of services, drugs, devices, products, and procedures enumerated in the statute. While plans may use reasonable medical management for services other than contraception and abortion, such management must not undermine RHEA’s requirement for coverage without cost sharing of the services described in ORS 743A.067(2).

    Policy Summary
    PayerDivision of Financial Regulation, Department of Consumer and Business Services
    PolicyDirector's expectations for health benefit plans under the Oregon Reproductive Health Equity Act
    Policy CodePolicy DFR 2025-3
    Change TypeNo material change
    Effective DateMar 24, 2025
    Last ReviewMar 24, 2025
    Next Review Date
    Key ActionDo not require prior authorization, step therapy, or other utilization review for medically appropriate covered contraceptives; provide prescribed alternatives when a covered therapeutic equivalent is medically inadvisable.
    SourceLink
    On This Page
    Coverage Criteria for Reproductive Health ServicesCoding and Screening DetailsProvider Actions, Notification & Utilization ManagementKey DefinitionsBackground and Scope
    Prohibited denialsDenying a refill that prevents continuous use of prescribed contraception (e.g., denying a refill before an enrollee requires it for continuous use) may violate RHEA and lead to enforcement action.
    Administration expectationCarriers and pharmacy benefit managers should administer 'refill too soon' policies to ensure enrollees can use oral contraception as directed by their health care provider (example: continuous-use 21-day refill cycle).

    Step therapy and other utilization review techniques are prohibited for medically appropriate covered contraceptives; plans must not require stepwise failure prior to coverage of an FDA‑approved contraceptive.

    Step Therapy

    Prohibition on step therapy

    ORS 743A.067(2)(j)(D) prohibits health benefit plans from requiring prior authorization, step therapy, or other utilization review techniques for medically appropriate covered contraceptive drugs, devices, or products.

    Denial Risk

    Document and justify denials under ORS 743A.067(7)

    When denying a RHEA‑listed service for a reason allowed under ORS 743A.067(7), the carrier must document the reason for the denial and be able to demonstrate why it was appropriate to apply that criterion to the particular claim.

    • Provide the enrollee with all appeal rights required under ORS 743B.250.
    Documentation Required

    Provider notification process for medically inadvisable contraceptives

    Carriers must establish and maintain an easily accessible, transparent, and sufficiently expedient process by which a health care provider may notify the carrier that a covered therapeutic equivalent is medically inadvisable for a particular enrollee and obtain coverage for the prescribed alternative.

    • Process must operate within a timeframe and manner that accounts for medical exigencies.
    • If treated as an exceptions process, it must not be unduly burdensome on enrollees or providers.
    Denial Risk

    Permissible denial reasons under ORS 743A.067(7)

    A carrier may deny coverage for RHEA services only for reasons listed in ORS 743A.067(7) (e.g., experimental or investigational treatments, clinical trials except as provided, nonconforming to accepted medical practice, insufficient medical evidence, or abortion if the carrier is exempt).

    • Carriers must document rationale and provide required appeal rights when denying for these reasons.
    Denial Risk

    Denial triggers: refill thresholds and refusal of prescribed alternatives

    Denials based on 'refill too soon' policies that prevent continuous use of a prescribed contraceptive, or denials that refuse coverage for a prescribed therapeutic equivalent after a provider notifies the plan, are inconsistent with RHEA and may lead to enforcement action.

    • Example: Failing to cover a 12‑month supply prescribed by a provider is impermissible.
    • Example: Refusing a brand prescription after provider notification that a generic is medically inadvisable is impermissible.
    ImplicationPlans may cover a therapeutic equivalent instead of a requested contraceptive provided at least one therapeutically equivalent version is covered, but must provide exceptions when medically inadvisable for the enrollee.
    RHEA listed service
    DefinitionA service, drug, device, product, or procedure described in ORS 743A.067(2)(b) through (l).
    ExclusionsDoes not include well-woman care under ORS 743A.067(2)(a) and additional preventive services for women under ORS 743A.067(2)(m).
    ContextTerm used to identify items subject to RHEA's coverage and management rules.
    Prior authorization (for purposes of RHEA)
    DefinitionA form of utilization review that requires a provider or enrollee to request a determination by an insurer, prior to the provision of health care that is subject to utilization review, that the insurer will provide reimbursement for the health care requested.
    Relevance to RHEAPrior authorization, step therapy, or other utilization review techniques are prohibited for medically appropriate covered contraceptives under ORS 743A.067(2)(j)(D).
    Enforcement implicationRequiring an exemption or prior request before covering an FDA-approved contraceptive with no therapeutic equivalent would constitute prohibited prior authorization.